Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy

Genetic mutations lead to the production of mutated proteins from which peptides are presented to T cells as cancer neoantigens. Evidence suggests that T cells that target neoantigens are the main mediators of effective cancer immunotherapies. Although algorithms have been used to predict neoantigen...

Full description

Bibliographic Details
Main Authors: Peng Bai, Yongzheng Li, Qiuping Zhou, Jiaqi Xia, Peng-Cheng Wei, Hexiang Deng, Min Wu, Sanny K. Chan, John W. Kappler, Yu Zhou, Eric Tran, Philippa Marrack, Lei Yin
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
cancer immunology
major histocompatibility complex (mhc)
vaccine
neoantigen prediction
antigen immunogenicity
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1868130

Internet

http://dx.doi.org/10.1080/2162402X.2020.1868130

Similar Items